{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:06:20Z","timestamp":1788375980147,"version":"build-2803163510"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007224","name":"National Foundation for Science and Technology Development","doi-asserted-by":"publisher","award":["108.06-2018.309"],"award-info":[{"award-number":["108.06-2018.309"]}],"id":[{"id":"10.13039\/100007224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Major advances in the treatment of multiple myeloma (MM) have been achieved by effective new agents such as proteasome inhibitors, immunomodulatory drugs, or monoclonal antibodies. Despite significant progress, MM remains still incurable and, recently, cellular immunotherapy has emerged as a promising treatment for relapsed\/refractory MM. The emergence of chimeric antigen receptor (CAR) technology has transformed immunotherapy by enhancing the antitumor functions of T cells and natural killer (NK) cells, leading to effective control of hematologic malignancies. Recent advancements in gene delivery to NK cells have paved the way for the clinical application of CAR-NK cell therapy. CAR-NK cell therapy strategies have demonstrated safety, tolerability, and substantial efficacy in treating B cell malignancies in various clinical settings. However, their effectiveness in eliminating MM remains to be established. This review explores multiple approaches to enhance NK cell cytotoxicity, persistence, expansion, and manufacturing processes, and highlights the challenges and opportunities associated with CAR-NK cell therapy against MM. By shedding light on these aspects, this review aims to provide valuable insights into the potential of CAR-NK cell therapy as a promising approach for improving the treatment outcomes of MM patients.<\/jats:p>","DOI":"10.3389\/fonc.2023.1275076","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:01:22Z","timestamp":1699009282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment"],"prefix":"10.3389","volume":"13","author":[{"given":"Son Hai","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Hong","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao Thi Phuong","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Thien","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manh-Cuong","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Hung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202049028","article-title":"Human NK cells, their receptors and function","volume":"51","author":"Quatrini","year":"2021","journal-title":"Eur J Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2567.2009.03123.x","article-title":"Natural killer cell cytotoxicity: how do they pull the trigger","volume":"128","author":"Topham","year":"2009","journal-title":"Immunology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.32","article-title":"The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies","volume":"5","author":"Dosani","year":"2015","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive cellular therapies: the current landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch"},{"key":"B8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/356607a0","article-title":"CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones","volume":"356","author":"Harding","year":"1992","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.177.1.165","article-title":"Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7\/BB1","volume":"177","author":"Tan","year":"1993","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00732-6","article-title":"Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy","volume":"18","author":"Zhang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1274","article-title":"CAR-NK cells: the next wave of cellular therapy for cancer","volume":"10","author":"Daher","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.832765","article-title":"Special chimeric antigen receptor (CAR) modifications of T cells: A review","volume":"12","author":"Miao","year":"2022","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0421-7","article-title":"A safe and potent anti-CD19 CAR T cell therapy","volume":"25","author":"Ying","year":"2019","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1119354","article-title":"Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival","volume":"5","author":"Genssler","year":"2016","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.03.071","article-title":"Impact of scFv structure in chimeric antigen receptor on receptor expression efficiency and antigen recognition properties","volume":"527","author":"Fujiwara","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/molecules16053675","article-title":"High affinity, developability and functional size: the holy grail of combinatorial antibody library generation","volume":"16","author":"Ponsel","year":"2011","journal-title":"Molecules"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159289","article-title":"Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma","volume":"140","author":"Cao","year":"2022","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-154025","article-title":"Dual chimeric antigen receptor approach combining novel tumor targeting strategies circumvents antigen escape in multiple myeloma","volume":"138","author":"Reiser","year":"2021","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-4077","article-title":"Abstract 4077: Dual-targeted CAR-NK cell therapy: optimized CAR design to prevent antigen escape and elicit a deep and durable response in multiple myeloma","volume":"83","author":"Yang","year":"2023","journal-title":"Cancer Res"},{"key":"B34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","article-title":"Nanobody-based CAR-T cells for cancer immunotherapy","volume":"10","author":"Safarzadeh Kozani","year":"2022","journal-title":"biomark Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1817147116","article-title":"Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice","volume":"116","author":"Xie","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"103964","DOI":"10.1016\/j.cellimm.2019.103964","article-title":"The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma","volume":"345","author":"Feinberg","year":"2019","journal-title":"Cell Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J"},{"key":"B40","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1038\/s41467-022-35127-2","article-title":"Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma","volume":"13","author":"Cichocki","year":"2022","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166167","article-title":"Anti-BCMA-CAR NK cells expressing soluble TRAIL: promising therapeutic approach for multiple myeloma in combination with bortezomib and \u03b3-secretase inhibitors","volume":"140","author":"Motais","year":"2022","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170501","article-title":"FT555: off-the-shelf CAR-NK cell therapy co-targeting GPRC5D and CD38 for the treatment of multiple myeloma","volume":"140","author":"Reiser","year":"2022","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166994","article-title":"Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma","volume":"140","author":"Dhakal","year":"2022","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell Malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"B46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00109-015-1327-6","article-title":"Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors","volume":"94","author":"Suerth","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.671519","article-title":"A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell Malignancies","volume":"14","author":"Shimasaki","year":"2012","journal-title":"Cytotherapy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30217","article-title":"Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival","volume":"139","author":"Oelsner","year":"2016","journal-title":"Int J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.10.009","article-title":"Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma","volume":"19","author":"Oelsner","year":"2017","journal-title":"Cytotherapy"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03123","article-title":"High cytotoxic efficiency of lentivirally and alpharetrovirally engineered CD19-specific chimeric antigen receptor natural killer cells against acute lymphoblastic leukemia","volume":"10","author":"M\u00fcller","year":"2019","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12810","article-title":"CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell Malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J Cell Mol Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32269","article-title":"Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth","volume":"145","author":"Oelsner","year":"2019","journal-title":"Int J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0114","article-title":"Targeting CD20+ Aggressive B-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice","volume":"3","author":"Chu","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1341031","article-title":"Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice","volume":"6","author":"Chu","year":"2017","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020321","article-title":"Targeting CD38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-CARs)","volume":"9","author":"Hambach","year":"2020","journal-title":"Cells"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22626","article-title":"Targeting T-cell Malignancies using anti-CD4 CAR NK-92 cells","volume":"8","author":"Pinz","year":"2017","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.6.2932","article-title":"Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome","volume":"165","author":"Tangye","year":"2000","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1250051","article-title":"Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma","volume":"5","author":"Leivas","year":"2016","journal-title":"Oncoimmunology"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0312","article-title":"Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia","volume":"10","author":"Berrien-Elliott","year":"2020","journal-title":"Cancer Discov"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128480","article-title":"Setting traps for NKG2A gives NK cell immunotherapy a fighting chance","volume":"129","author":"Cichocki","year":"2019","journal-title":"J Clin Invest"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J Clin Invest"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02003-x","article-title":"KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape","volume":"28","author":"Li","year":"2022","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.06.004","article-title":"In vivo generation of CAR T cells in the presence of human myeloid cells","volume":"26","author":"Ho","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201529","article-title":"A robust platform for expansion and genome editing of primary human natural killer cells","volume":"218","author":"Huang","year":"2021","journal-title":"J Exp Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A genetically engineered primary human natural killer cell platform for cancer immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1083","article-title":"Applications of CRISPR genome editing to advance the next generation of adoptive cell therapies for cancer","volume":"11","author":"Fix","year":"2021","journal-title":"Cancer Discov"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-cell transduction with baboon envelope pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00957","article-title":"Human CAR NK cells: A new non-viral method allowing high efficient transfection and strong tumor cell killing","volume":"10","author":"Ingegnere","year":"2019","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.02.023","article-title":"Manufacturing NKG2D CAR-T cells with piggyBac transposon vectors and K562 artificial antigen-presenting cells","volume":"21","author":"Tay","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.953849","article-title":"Overcoming tumor resistance mechanisms in CAR-NK cell therapy","volume":"13","author":"Valeri","year":"2022","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006200","article-title":"CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi Kararoudi","year":"2020","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-edited CAR T cells for combinational therapy against T cell Malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"crossref","first-page":"A229","DOI":"10.1136\/jitc-2021-SITC2021.216","article-title":"216 Multiplex base editing of NK cell to enhance cancer immunotherapy","volume":"9","author":"Minjing","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.ymthe.2021.10.011","article-title":"IL12 integrated into the CAR exodomain converts CD8(+) T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors","volume":"30","author":"Hombach","year":"2022","journal-title":"Mol Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(03)00043-1","article-title":"The biology of IL-12: coordinating innate and adaptive immune responses","volume":"14","author":"Watford","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20212434","article-title":"Differential IL-12 signaling induces human natural killer cell activating receptor-mediated ligand-specific expansion","volume":"219","author":"Shemesh","year":"2022","journal-title":"J Exp Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1182\/blood.V128.22.816.816","article-title":"IL-18 secreting CAR T cells enhance cell persistence, induce prolonged B cell aplasia and eradicate CD19+ Tumor cells without need for prior conditioning","volume":"128","author":"Avanzi","year":"2016","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1403-0","article-title":"Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin","volume":"62","author":"Srivastava","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.22809","article-title":"Effect of IL-18 on the expansion and phenotype of human natural killer cells: application to cancer immunotherapy","volume":"14","author":"Senju","year":"2018","journal-title":"Int J Biol Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011532","article-title":"Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy","volume":"139","author":"Berrien-Elliott","year":"2022","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6997","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Sci Adv"},{"key":"B104","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022842","article-title":"Human tumour immune evasion via TGF-\u03b2 blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity","volume":"6","author":"Wilson","year":"2011","journal-title":"PloS One"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.3784","article-title":"TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells","volume":"181","author":"Trotta","year":"2008","journal-title":"J Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41392-020-00436-9","article-title":"Targeting TGF\u03b2 signal transduction for cancer therapy","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2121-4","article-title":"An IL-15 superagonist\/IL-15R\u03b1 fusion complex protects and rescues NK cell-cytotoxic function from TGF-\u03b21-mediated immunosuppression","volume":"67","author":"Fujii","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3183","article-title":"Engineering the TGF\u03b2 Receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma","volume":"25","author":"Burga","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1021\/acscentsci.9b00956","article-title":"Glycoengineering of natural killer cells with CD22 ligands for enhanced anticancer immunotherapy","volume":"6","author":"Wang","year":"2020","journal-title":"ACS Cent Sci"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018330","article-title":"Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden","volume":"141","author":"Biondi","year":"2023","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00365-x","article-title":"CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-183772","article-title":"CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf\u2013mediated interactions with bone marrow stromal cells","volume":"113","author":"Tai","year":"2009","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01559-4","article-title":"CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells","volume":"36","author":"O'Neal","year":"2022","journal-title":"Leukemia"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"key":"B121","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J Cell Immunother"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int J Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2018.03.029","article-title":"A semi-automated, high-purity process for natural killer (NK) cell manufacturing in a rocking bioreactor","volume":"20","author":"Gratch Y","year":"2018","journal-title":"Cytotherapy"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1480241","article-title":"Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy","volume":"14","author":"Meng","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01866-5","article-title":"Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India","volume":"58","author":"Palani","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B126","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000495772","article-title":"Functionality and cell senescence of CD4\/ CD8-selected CD20 CAR T cells manufactured using the automated cliniMACS prodigy\u00ae Platform","volume":"46","author":"Aleksandrova","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"B127","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","article-title":"Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center","volume":"20","author":"Zhu","year":"2018","journal-title":"Cytotherapy"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03724.x","article-title":"Natural killer cells: a review of manufacturing and clinical utility","volume":"53","author":"Koepsell","year":"2013","journal-title":"Transfusion"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00578","article-title":"The application of natural killer cell immunotherapy for the treatment of cancer","volume":"6","author":"Rezvani","year":"2015","journal-title":"Front Immunol"},{"key":"B130","article-title":"Cryoprotectants: the essential antifreezes to protect life in the frozen state","volume":"25","author":"Fuller","year":"2004","journal-title":"Cryo Lett"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.2014010931","article-title":"Clinical grade purification and expansion of natural killer cells","volume":"19","author":"Lapteva","year":"2014","journal-title":"Crit Rev Oncog"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2020.05.001","article-title":"Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation","volume":"22","author":"Damodharan","year":"2020","journal-title":"Cytotherapy"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1080\/14653240902807034","article-title":"Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells","volume":"11","author":"Berg","year":"2009","journal-title":"Cytotherapy"},{"key":"B134","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1038\/s41467-020-19094-0","article-title":"Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells","volume":"11","author":"Mark","year":"2020","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J Immunother"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.700767","article-title":"Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705100","article-title":"Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres","volume":"36","author":"Windrum","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B138","doi-asserted-by":"publisher","first-page":"16223","DOI":"10.1038\/s41598-018-34638-7","article-title":"Characterizing the \"sweet spot\" for the preservation of a T-cell line using osmolytes","volume":"8","author":"Pi","year":"2018","journal-title":"Sci Rep"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.cryobiol.2010.10.160","article-title":"Response of the cell membrane-cytoskeleton complex to osmotic and freeze\/thaw stresses","volume":"61","author":"Ragoonanan","year":"2010","journal-title":"Cryobiology"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.07.004","article-title":"Preservation of cell-based immunotherapies for clinical trials","volume":"21","author":"Li","year":"2019","journal-title":"Cytotherapy"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.861681","article-title":"Cryopreserved PM21-particle-expanded natural killer cells maintain cytotoxicity and effector functions in vitro and in vivo","volume":"13","author":"Oyer","year":"2022","journal-title":"Front Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.02.006","article-title":"Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment","volume":"18","author":"Oyer","year":"2016","journal-title":"Cytotherapy"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci Transl Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841107","article-title":"iPSC-derived natural killer cell therapies - expansion and targeting","volume":"13","author":"Goldenson","year":"2022","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162712","article-title":"High-density cryopreservation of off-the-shelf CAR-NK cells facilitates on-demand treatment access","volume":"140","author":"Chang","year":"2022","journal-title":"Blood"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151185","article-title":"Safety and efficacy of FT596, a first-in-class, multi-antigen targeted, off-the-shelf, iPSC-derived CD19 CAR NK cell therapy in relapsed\/refractory B-cell lymphoma","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146602","article-title":"A phase 1 study of NKX019, a CD19 chimeric antigen receptor natural killer (CAR NK) cell therapy, in subjects with B-cell Malignancies","volume":"138","author":"Dickinson","year":"2021","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879452","article-title":"A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma","volume":"13","author":"Bae","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1275076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T11:01:30Z","timestamp":1699009290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1275076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":151,"alternative-id":["10.3389\/fonc.2023.1275076"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1275076","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"article-number":"1275076"}}